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Abstract
Abnormalities of striatal glutamate neurotransmission may play a role in the pathophysiology of Parkinson’s disease and
may respond to neurosurgical interventions, specifically stimulation or lesioning of the subthalamic nucleus (STN). The
major glutamatergic afferent pathways to the striatum are from the cortex and thalamus, and are thus likely to be sources of
striatal neuronally-released glutamate. Corticostriatal terminals can be distinguished within the striatum at the electron
microscopic level as their synaptic vesicles contain the vesicular glutamate transporter, VGLUT1. The majority of terminals
which are immunolabeled for glutamate but are not VGLUT1 positive are likely to be thalamostriatal afferents. We
compared the effects of short term, high frequency, STN stimulation and lesioning in 6-hydroxydopamine (6OHDA)-lesioned
rats upon striatal terminals immunolabeled for both presynaptic glutamate and VGLUT1. 6OHDA lesions resulted in a small
but significant increase in the proportions of VGLUT1-labeled terminals making synapses on dendritic shafts rather than
spines. STN stimulation for one hour, but not STN lesions, increased the proportion of synapses upon spines. The density of
presynaptic glutamate immuno-gold labeling was unchanged in both VGLUT1-labeled and -unlabeled terminals in 6OHDA-
lesioned rats compared to controls. Rats with 6OHDA lesions+STN stimulation showed a decrease in nerve terminal
glutamate immuno-gold labeling in both VGLUT1-labeled and -unlabeled terminals. STN lesions resulted in a significant
decrease in the density of presynaptic immuno-gold-labeled glutamate only in VGLUT1-labeled terminals. STN interventions
may achieve at least part of their therapeutic effect in PD by normalizing the location of corticostriatal glutamatergic
terminals and by altering striatal glutamatergic neurotransmission.
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Introduction
Deep brain stimulation (DBS) and lesioning of basal ganglia
targets have become state-of-the-art therapies for selected patients
with moderately advanced Parkinson’s disease (PD). However, the
mechanisms by which neurosurgical interventions improve the
symptoms of PD are not well understood - whether clinical benefit
is achieved by neuronal excitation, inhibition, modulation, or
some combination of these. Stimulation and lesioning have similar,
but not identical, clinical effects. The effects of lesioning are by
definition inhibitory, as neuronal structures are destroyed, but
there is evidence to support both inhibitory and excitatory
mechanisms of stimulation at the neuronal level [1,2].
Using microdialysis we have previously found changes in striatal
extracellular glutamate levels in rats which had undergone 6-
hydroxydopamine (6OHDA) lesions, subthalamic nucleus (STN)
lesions and STN stimulation [3]. The relative contributions of the
different glutamatergic inputs to the striatum in the setting of
dopamine depletion are not well understood, but have implica-
tions, for example, for the possible manipulation of a particular
pathway or neurotransmitter for therapeutic ends. In order to
determine the neuronal source of these changes in glutamate, and
to provide insights into alterations in basal ganglia functioning in
this situation we performed electron microscopic (EM) studies
using immuno-gold to label glutamate [4] and antibodies against
the glutamate transporter VGLUT1 to identify corticostriatal
afferents [5–8].
We focused upon VGLUT1-immunolabeled glutamatergic,
presumptively corticostriatal, synapses [5–8], in order to study
changes to this pathway in the setting of dopamine depletion and
of surgical manipulations of the STN. The other major
glutamatergic input to striatum from the thalamic centromedian
parafascicular (CM-pf) nucleus contains only VGLUT2. Although
VGLUT1 mRNA is present in the thalamic motor relay nuclei
[9,10], which have a lesser, although still significant striatal input,
immunocytochemical studies suggest that VGLUT1 is found only
in corticostriatal terminals [6,7,11–13]. VGLUT1 and VGLUT2
afferents both provide similar innervation to D1 and D2-receptor-
bearing striatal neurons [14].
We hypothesized that corticostriatal and non-corticostriatal
terminals would be differentially affected in the different
experimental groups, providing information about the neuronal
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state and following STN surgical interventions. We studied the
localization of VGLUT1-labeled synaptic terminals in 6OHDA-
lesioned rats, and following short term, high frequency STN
stimulation and STN lesions. The localization of glutamatergic
inputs upon heads or necks of spines, or upon the shafts of
dendrites of striatal medium spiny neurons is likely to play a
critical role in the integration and processing of incoming neuronal
signals [15]. Dopaminergic and thalamic inputs located upon the
shafts of dendrites may have a general modulatory effect upon
signals from glutamatergic inputs on spine heads [15]. We also
examined effects of STN manipulations in 6OHDA-lesioned rats
upon pre- and post-synaptic glutamate immunolabeling in
VGLUT1-labeled vs. -unlabeled terminals.
Materials and Methods
Ethics statement
All animal procedures were approved by the Institutional
Animal Care and Use Committee of the James J. Peters Veterans
Affairs Medical Center (protocol #6531-04-020).
Experimental groups
Young adult (200–250 g) male Sprague-Dawley rats were used.
Five groups of rats were used for EM studies; controls (n=8),
6OHDA lesions alone (n=6), 6OHDA+ STN electrolytic lesions
(n=5), and 6OHDA+sham (n=3) or active (n=4) STN
stimulation.
6-hydroxydopamine lesions
After acclimation, animals were anaesthetized with intraperito-
neal injections of ketamine (40 mg/kg) and xylazine (5 mg/kg),
and placed in a stereotaxic frame (Kopf, Tujunga, CA). Two
injections of 12 mg 6OHDA (Sigma; 2 ml injections of 6 mg/ml in
0.9 M NaCL, with 0.2 mg/ml L-ascorbate on ice) were performed
as previously reported [3,16], targeting the substantia nigra, pars
compacta (SNc), at 2 sites, 1.8 mm lateral and 5.6 mm posterior to
bregma, and 1.6 mm lateral and 5.8 mm posterior, with the aim
of producing a relatively complete lesion. 10–14 days later, rats
were injected intraperitoneally with amphetamine (2.5 mg/kg).
Only rats which turned .50 turns/10 minutes were used for
subsequent procedures. The extent of the lesion was confirmed
with immunohistochemistry against tyrosine hydroxylase (TH)
[3,16,17] (Fig. 1A).
Subthalamic nucleus lesions
Two weeks after 6OHDA lesions, one group of rats (n=5)
underwent electrolytic ablation of the ipsilateral STN. This was
performed using a monopolar lesioning electrode (Fred Haer & Co.
Inc., Bowdoinham, ME) at 2 sites (2.3 mm lateral, 3.4 and 3.6 mm
posterior to bregma, 7.9 mm ventral to dura) [3,16]. Following
perfusion of the animals with fixative (see Electron microscopy), the
brains were serially cut at 60 mm through the STN using a
vibratome (Ted Pella, Redding, CA). All sections through the
lesioned STN were mounted on glass slides and stained with
thionin. The area of the STN was determined on serial sections and
the percent of the STN which had been lesioned was determined on
each section for each animal. Results were only analyzed from
animals in which at least 50% of the STN was lesioned and there
was no significant damage to the surrounding tissue (Fig. 1B).
STN stimulating electrode placement and stimulation
For STN stimulation, two weeks after 6OHDA lesions, a
stainless steel, bipolar, concentric stimulating microelectrode (tip
diameter 200 mm; FHC) was implanted into the ipsilateral STN
(2.3 mm lateral, 3.6 mm posterior to bregma, 7.9 mm ventral to
dura) [3,16].
One week later, for animals undergoing active stimulation
(n=4), the implanted stimulating electrode was connected to a
rectangular pulse generator (Pulsar Digital Stimulator 6-bp, FHC)
with the inner pole negative, and stimulation was carried out at
300 mA at 130 Hz [3,16,18,19] for one hour prior to euthanasia.
No involuntary movements were noted during stimulation. A
parallel group of animals (n=3) had electrodes placed but did not
undergo stimulation (sham stimulation). Following perfusion with
fixative, brains were serially sectioned through the STN and
mounted for confirmation of the location of the electrode track.
Only those animals in which the electrode track was found within
the STN were used for the final analysis.
Electron microscopy
Animals were euthanized for EM one week after STN surgery
with a lethal dose of anesthetic (ketamine 80 mg/kg, xylazine
10 mg/kg). The chest cavity was opened for transcardial perfusion
with 6 ml of heparin (1000 units/ml) in 0.1 M HEPES buffer
pH 7.3, followed by 300 mls of 2% paraformaldehyde/0.1%
glutaraldehyde/0.1% picric acid in the same buffer, all at room
temperature. All animals from each of the experimental groups
were perfused with fixative on the same day in order to limit the
Figure 1. Nigral and subthalamic lesions. (A) Depletion of TH-
immunoreactive neurons in left substantia nigra pars compacta, as
compared with the unlesioned right side (arrows). (B) Electrolytic
ablation of left subthalamic nucleus (white arrow; outlined by black
dotted line); results were only analyzed from animals in which at least
50% of the subthalamic nucleus was lesioned; the intact contralateral
subthalamic nucleus is indicated on the right side (small black arrow;
dashed outline). CP=cerebral peduncle, SNc=substantia nigra, pars
compacta, VTA=ventral tegmental area.
doi:10.1371/journal.pone.0032919.g001
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This avoided any potential problems due to brain anoxia or tissue
perfusion that would influence the glutamate immuno-gold
labeling results.
For EM immunolabeling for VGLUT1 and glutamate immuno-
gold labeling the rostral block of brain tissue was sectioned on the
vibratome at 60 mm, and the dorsolateral striatum dissected. This
is equivalent to +1.0 mm anterior [20], which receives a
glutamatergic projection from the somatosensory cortex [21] and
is involved in the motor circuit.
Striatal tissue was processed for EM pre-embedding diamino-
benzidine (DAB) immunolabeling [VGLUT1 (1:10,000), rabbit
polyclonal, Synaptic Systems, Germany] as previously described
[22], with modifications below using a new microwave procedure
[23]. Tissue was incubated in the microwave (Pelco BioWave, Ted
Pella, Inc) for 5 minutes, 550 watts (W), at 35uC with the vacuum
off (all the remaining steps occurred at this temperature) in 10 mM
sodium citrate, pH 6.0, rinsed in 0.1 M phosphate buffer (PB) for
261 min at 150 W, with the vacuum off, exposed to 3% hydrogen
peroxide at 150 W for 1 min with the vacuum on, rinsed in PB at
150 W for 261 min with the vacuum off, exposed to 0.5% Triton
X-100 for 5 min, 550 W with the vacuum on, washed in PB for
261 min at 200 W with the vacuum off, then exposed to the
primary antibody for 12 minutes at 200 W, 4 times using the
following cycle: 2 min on, 2 min off, 2 min on, 5 min off, all on a
continuous vacuum. The tissue is then rinsed in PB, 261 min, at
150 W with the vacuum off, then exposed to the secondary
antibody (biotinylated goat anti-rabbit, 1:500; Vector Labs) for
15 minutes at 200 W for two cycles of the following: 4 min on,
3 min off, 4 min on, 5 min off, all on a continuous vacuum. The
tissue is then rinsed in PB, 261 min, at 150 W with the vacuum
off, then exposed to ABC (Vector Elite Kit, 1 ml/ml of solution A
and B in PB) for 11 minutes at 150 W, under vacuum, using the
following cycle: 4 min on, 3 min off, 4 min on. The tissue is then
rinsed in PB, 261 min, at 150 W with the vacuum off and then
exposed to DAB (0.5 mg/ml+1.5% hydrogen peroxide) for up to
10 minutes at room temperature.
The tissue was embedded in epoxy for immuno-gold labeling as
previously described [4]. All tissue from each of the experimental
groups was cut and processed on the same day in order to limit the
variables that may occur by cutting and processing tissue on
different days.
Post-embedding immuno-gold electron microscopy was per-
formed [24] with modifications [4]. The glutamate antibody (non-
affinity purified, rabbit polyclonal; Sigma Chemical Co., St. Louis,
MO), as previously characterized [24], was diluted 1:250 in TBST
7.6. Aspartate (1 mM) was added to the glutamate antibody
mixture 24 hours prior to incubation with the thin-sectioned tissue
to prevent any cross-reactivity with aspartate within the tissue. The
secondary antibody was goat anti-rabbit IgG (Amersham,
Arlington Heights, IL; diluted 1:25 in TBST pH 8.2), tagged
with 10 nm gold particles. We previously reported that incubation
of the antibody with 3 mM glutamate resulted in no immuno-gold
labeling, showing the specificity of the glutamate labeling [25].
Photographs (10/animal) of VGLUT1-labeled and -unlabeled
terminals were taken from a single 50 mm mesh grid (1 thin
section/grid, 1 photograph/grid square) throughout the neuropil
(an area containing the highest numbers of synapses) at a final
magnification of 640,000 by an individual blinded to the
experimental groups, using a digital camera (AMT, Danvers,
MA). Photographs were randomly taken throughout the neuropil,
the area containing the highest number of synapses, but only in
areas where there was VGLUT1/DAB reaction product. Such
labeled structures formed the lowest part of the photograph in
order to ensure that VGLUT-1-unlabeled terminals were not
counted if they were found lower than the deepest VGLUT1-
labeled structures. VGLUT1/DAB-labeled or -unlabeled termi-
nals were analyzed only if there was an accumulation of synaptic
vesicles within the nerve terminal and the terminal was seen
making an asymmetrical synaptic contact with an underlying
dendrite or dendritic spine.
For quantification of glutamate labeling, the number of
immuno-gold particles located either within, or at least touching
the synaptic vesicle membrane (i.e. vesicular pool), the number
located outside the synaptic vesicles (i.e. the cytoplasmic pool,
which is most likely the origin of the glutamate for the cystine-
glutamate antiporter), and those associated with mitochondria,
were counted. The vesicular and cytoplasmic pools were
combined since the cytoplasmic pool is very small (,10%)
compared to the vesicular pool [4]. We have reported that nerve
terminals making a symmetrical contact contain GABA [4], the
precursor for which is glutamate. Therefore nerve terminals
making a symmetrical contact will naturally contain some
glutamate immunolabeling and cannot be considered immuno-
negative as a way of determining a ratio between glutamatergic
and GABA-ergic terminals [4,26]. The metabolic pool is also
relatively small and thus unlikely to be a major source of variation
in labeling intensity. In the current study, we find no differences
in the density of mitochondrial glutamate immuno-gold labeling
between the control compared to all other treatment groups in
either the VGLUT1-labeled or -unlabeled terminals (data not
shown).
For all VGLUT1-immunolabeled terminals and non-
VGLUT1-labeled terminals (Fig. 2) we measured the density
of immuno-gold labeling in each terminal, to determine the
effects of the lesions upon each class (i.e. corticostriatal versus
non-corticostriatal) of striatal glutamatergic afferents. The
density of gold particles/mm
2 of nerve terminal area for the
vesicular/cytoplasmic and metabolic pools was determined for
each animal and the mean density for each treatment group
calculated. Background labeling was determined within glial cell
processes and was found to be 10 immuno-gold-labeled
particles/mm
2 [25]. This was subtracted from the density of
presynaptic immuno-gold-labeled glutamate glutamate within
the nerve terminals for all treatment groups. We also examined
the density of immuno-gold-labeling in post-synaptic spines, as
changes in post-synaptic glutamate may reflect alterations in
synaptic metabolic activity. In addition, since the glutamate
transporter, EAAC1 (excitatory amino acid carrier 1) is neuronal
and located post-synaptically, changes in glutamate density
within the spine may also reflect alterations in neuronal uptake
of glutamate.
In order to obtain an estimate of whether there was any change
in number of glutamatergic synapses following dopamine
depletion, we counted the number of synapses in each photo-
graphic field of view (32 mm
2) upon either spines or dendritic
shafts, made by either VGLUT1-labeled or –unlabeled terminals.
In addition, the percentage of VGLUT1-labeled or -unlabeled
nerve terminals making an asymmetrical synaptic contact onto a
dendrite or dendritic spine was calculated. The same nerve
terminals that were part of the analysis for the density of glutamate
immuno-gold labeling (see above) were also used to determine
what percentage were contacting either a dendrite or spine.
The analysis of the treatment groups was carried out in a
blinded fashion. The differences between treatment groups were
analyzed with a one-way ANOVA and significant main effects
were further characterized using the Fisher post hoc test for
comparison of multiple means.
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Unaffected parameters
In none of the groups did we see a significant change in the
proportions of terminals at asymmetric synapses which were
VGLUT1-labeled (approximately 55%) as opposed to -unlabeled
(approximately 45%) (data not shown). This percentage is larger
than previously reported in the rat [6] (34.8%) but was similar to
that in the monkey (51.9%) [7]. In the MPTP-treated primate
there was a relative increase in VGLUT1-labeled terminals [7],
which may be at least in part attributable to differences in time
course and methodology.
In estimating the numbers of synapses/32 mm
2 made by
glutamatergic terminals upon spines or shafts, we did not find
statistically significant differences between the experimental groups
(Table 1). There was, however, a decrease of 18.4% in VGLUT1-
labeled terminals and a decrease of 18.7% in non-VGLUT1-
labeled terminals making an asymmetrical synaptic contact
between controls and 6OHDA-lesioned rats. The total number
of all glutamatergic synapses/32 mm
2 decreased by 18.5%
between the controls and the 6OHDA group, similar to the value
reported using formal stereology (19%) [27]. There was no change
between groups in cross-sectional area of terminals (data not
shown).
Localization of glutamatergic synapses in the control
group
We present the same data organized by experimental group
(Fig. 3) and by type of terminals (Fig. 4), in order to compare
groups. Of all VGLUT1-labeled glutamatergic (asymmetric)
synapses in the control group, 94% made synaptic contact onto
spines (Fig. 2A), similar to previous studies [6,7,28]. The
remaining 6% made contact on dendritic shafts (Fig. 3A). For
non-VGLUT1- labeled terminals, 84% synapsed onto dendritic
spines (Fig. 2A), and the remaining 16% contacted dendritic shafts
(Fig. 3A). This figure is higher than that reported by others for the
rodent (72%) [6] and monkey (approximately 55%) [7]. However,
it is within the range (60–85% in three rats) of specifically
VGLUT2-labeled terminals making synapses upon spines [28]. In
the current study, VGLUT1-unlabeled terminals account for both
Figure 2. Immuno-gold labeled glutamate particles in VGLUT1-labeled and -unlabeled terminals. (A) Control.E l e c t r o n
photomicrographs of VGLUT1-labeled (L-NT) and -unlabeled (UN-NT) nerve terminals making asymmetric synaptic contacts (arrow) onto dendritic
spines (SP). The 10 nm gold particles within the nerve terminals (see arrowhead in the L-NT) indicate the location of an antibody against glutamate.
The inserts show labeled details of a terminal containing VGLUT1-immunoreactive synaptic vesicles (above) and a terminal containing unlabeled
synaptic vesicles (below). (B) 6-OHDA lesion. L-NT and UN-NT both make asymmetric synaptic contacts (arrows) with SPs. The density of immuno-
gold labeling within these terminals is similar to that of the control group (A). (C) 6-OHDA/STN lesion: L-NT and UN-NT make asymmetric synaptic
contacts (arrows) with SPs. The density of nerve terminal immuno-gold labeling is significantly reduced compared to the control (A) and 6OHDA (B)
tissue. (D) 6-OHDA/STN stimulation. Both L-NT and UN-NT make asymmetrical synaptic contacts (arrows) with SPs. The density of nerve terminal
glutamate immuno-gold labeling is similar to that seen in the 6-OHDA/STN lesion group (C). (E) 6-OHDA/Sham-Stim. The L-NT makes an
asymmetric synaptic contact with the SP, and the UN-NT makes an asymmetric synaptic contact with a dendritic shaft (DEND). The density of nerve
terminal glutamate immuno-gold labeling is greater than in the 6-OHDA/STN lesion (C) and 6-OHDA/STN stimulation (D) tissue. Calibration bar:
0.25 microns.
doi:10.1371/journal.pone.0032919.g002
Table 1. Mean numbers of VGLUT1-labeled or –unlabeled
synapses on spines and shafts per field of view (32 mm
2) 6
standard deviation. Differences were not statistically
significant.
Group VGLUT1-labeled Non-VGLUT1-labeled
On spines On shafts On spines On shafts
Control 1.7560.39 0.1560.12 1.3260.27 0.2560.14
6OHDA 1.3160.24 0.2860.16 1.0660.24 0.3060.17
6OHDA+STN
lesion
1.3360.23 0.3160.16 1.1160.17 0.2360.16
6OHDA+STN
stimulation
1.4860.27 0.0960.08 1.1860.28 0.2560.12
6OHDA+sham
stimulation
1.960.61 0.3660.17 1.3760.15 0.3360.12
doi:10.1371/journal.pone.0032919.t001
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VGLUT1- nor VGLUT2-positive. Nearly 30% of the nerve
terminals making asymmetrical synaptic contacts do not label for
either VGLUT1 or VGLUT2 protein [6], thus we are unable to
draw firm conclusions about the identity of unlabeled terminals in
this study.
6OHDA lesions
Based upon our previously-published studies [3,16], rats which
rotated with amphetamine .50 turns/10 minutes had a mean
depletion of 90% of TH immunoreactivity of the substantia nigra
by optical densitometry as compared with the unlesioned side
(Fig. 1A).
Examining only VGLUT1-labeled terminals following dopa-
mine depletion (Fig. 3B), there was a significant decrease in the
percentage that made contact on spines compared to the control
group, from 94% to 82% (p,0.02; Fig. 4A). The percentage of
VGLUT1- labeled terminals making contact on shafts increased
from 6% in the control group to 18% in the 6OHDA- lesioned
group (p,0.02; Fig. 4B). For VGLUT1-unlabeled terminals alone,
there was no difference in the percentage of terminals making
contact with spines vs. shafts (82%:18%; Fig. 3B) between the
control and 6OHDA-lesioned group (Fig. 4C, 4D). This contrasts
with findings in the long-term MPTP-treated primate, in which
there was no difference [7].
In 6OHDA-lesioned rats, there was no difference in the density
of presynaptic glutamate immuno-gold-labeling (Fig. 2B) in either
VGLUT1-labeled (Fig. 5A) or -unlabeled (Fig. 5B) terminals
compared to controls.
6OHDA+STN lesions
For VGLUT1-labeled terminals alone, STN lesions (Fig. 1B) in
6OHDA- lesioned rats did not significantly change the percent-
ages making synaptic contact onto a spine (Fig. 2C) or shaft
(81%:19%; Fig. 3C) compared with the 6-OHDA group (Fig. 4A,
4B). There was similarly no effect upon the percentages of non-
VGLUT1-labeled terminals making contact onto spines or shafts
compared with the 6OHDA-lesioned group (83%:17%) (Fig. 4C,
4D).
Rats with 6OHDA+STN lesions showed a decrease in the
density of glutamate immuno-gold-labeling (Fig. 2C) of 41% in
VGLUT1-labeled terminals (p,0.05) as compared with 6OHDA-
lesioned rats alone (Fig. 5A). The density of glutamate immuno-
gold-labeling in unlabeled terminals was decreased by 30%, which
was not significant (Fig. 5B).
6OHDA+STN stimulation
STN stimulation increased the percentage of VGLUT1-labeled
terminals making contact on spines, and decreased the percentage
of synapses upon shafts (95%:5%; Fig. 3D) to values comparable to
Figure 3. Location of VGLUT1-labeled and -unlabeled terminals for each experimental group. (A) control (n=8), (B) 6OHDA-lesioned
(n=6), (C) 6OHDA+STN lesion (n=5), (D) 6OHDA+STN stimulation (n=4), (E) 6OHDA+ sham stimulation (electrode placement alone; n=3).
doi:10.1371/journal.pone.0032919.g003
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electrode placement alone (sham stimulation) (Fig. 4E).
Rats with 6OHDA lesions+STN stimulation showed a decrease
in nerve terminal glutamate immuno-gold-labeling (Fig. 2D) of
58% in VGLUT1-labeled (p,0.01; Fig. 5A) and of 47% in
unlabeled terminals (p,0.02; Fig. 5B) as compared with controls.
This was not seen with electrode placement alone (sham
stimulation) (Fig. 2E, 5A, 5B).
Post-synaptic glutamate labeling in dendritic spines
STN stimulation in 6OHDA-lesioned rats reduced the density
of glutamate immuno-gold labeling within spines post-synaptic to
VGLUT1-labeled terminals by 41%, which was non-significant
(p=0.17). However, for spines post-synaptic to non-VGLUT1-
labeled terminals, the reduction was 47%, which was statistically
significant (p=0.05) (Table 2). The significance of this is unclear
but may represent a metabolic response to increased synaptic
activity, or a compensation for increased presynaptic glutamate
release, and is possibly mediated by the glutamate transporter
EAAC1. For all other groups, there was no difference in the
density of glutamate immuno-gold labeling within spines com-
pared to the control group regardless of whether the presynaptic
nerve terminal was VGLUT1-labeled or -unlabeled.
Discussion
Comparison of STN stimulation and lesions
STN stimulation, but not STN lesions, returned the relative
distribution of the locations of VGLUT1-labeled glutamatergic
terminals to that seen in control rats (Fig. 6). This remodeling
suggests that DBS may achieve its therapeutic effect, at least in
part, by normalization of corticostriatal neurotransmission. As the
number of spines is significantly reduced in the setting of
dopamine depletion, both in rodents [29–33] and humans with
Parkinson’s disease [34,35], it is possible that STN stimulation
increases the number of spines available for synapses, maybe via a
cortical mechanism [31,36]. Quantitative stereological studies
would be required to demonstrate this. Plasticity of glutamatergic
Figure 4. Comparison of localization of VGLUT1-labeled and -unlabeled terminals between groups. Percentages of VGLUT1-labeled
terminals synapsing upon dendritic spines (A) and shafts (B) in the 5 experimental groups; control (n=8), 6OHDA-lesioned (n=6), 6OHDA+STN lesion
(n=5), 6OHDA+STN stimulation (n=4), and 6OHDA+ sham stimulation (electrode placement alone; n=3). In 6OHDA-lesioned animals, there was a
shift from synapses on spines to upon shafts (p,0.02), which was reversed by STN stimulation (p,0.05). Percentages of non-VGLUT1-labeled
terminals synapsing upon dendritic spines (C) and shafts (D). There were no significant differences between any of the experimental groups for
unlabeled terminals.
doi:10.1371/journal.pone.0032919.g004
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conditions, with alterations in proteins involved in remodeling
such as Arc, MEF-2 and Nurr77 [37]. Changes in morphology of
striatal neurons with pruning of dendritic spines are noted in cell
cultures depolarized by potassium within a few hours [37]. This
suggests that rapid remodeling occurs in the striatum in response
to changes in neuronal activity, and with changes in dopaminergic
state, whether direct [38,39] or indirect [40,41].
Synapse location did not change with STN lesions for
VGLUT1-unlabeled terminals, even when the density presynaptic
glutamate immuno-gold labeling was decreased, possibly implying
that this type of synaptic plasticity is of less importance for these
(non-corticostriatal) afferents. An alternative explanation is that
this finding indicates a more widespread mechanism of action of
STN stimulation as compared with STN lesioning, potentially
involving thalamostriatal pathways as well as corticostriatal. The
finding of changes within one hour is consistent with the
observation that the clinical response to DBS in PD is typically
seen within minutes [42], however, it is certainly likely that distinct
mechanisms come into play with sustained stimulation, which may
also explain the difference found here between lesions and short
term stimulation.
The mechanism by which DBS achieves its therapeutic effect is
unknown. Although some studies of the effects of STN stimulation
upon local neurons have reported inhibitory effects [43–46],
others have not [47–49]. An inhibitory effect of stimulation upon
STN neurons, with loss of drive of the GPi and disinhibition of the
thalamus, would fit our data into the classic model of basal ganglia
function. It is likely, however, that far more complex effects and
circuitry are involved when the STN is stimulated, such as direct
activation of nearby thalamostriatal fibres [50], or direct [51] or
antidromic activation of the cortex [52,53]. These mechanisms
might result in stimulation of corticostriatal fibres and result in the
remodeling we observed here. At a more system-wide level, DBS
appears to normalize aberrant oscillations within the basal ganglia
[54]. This widespread effect would not occur following an STN
lesion.
Another hypothesis is that changes in striatal glutamate release
and synaptic modeling may be secondary to alterations in striatal
dopamine levels. We have previously demonstrated that STN
stimulation affects striatal dopamine levels [16], possibly by an
effect upon the remaining nigral dopamine neurons, and thus
modulates striatal glutamate release via a presynaptic mechanism
[55,56].
Effects of 6OHDA lesions
6OHDA lesions resulted in a small but significant shift of
VGLUT1-labeled terminals from dendritic spines to shafts (Fig. 6),
possibly due to a loss of spines [29–35]. There is debate as to
whether spines are lost from both striatopallidal and striatonigral
medium spiny neurons. Some studies have found evidence for
spine loss only on D2 receptor-bearing striatopallidal neurons
which comprise the indirect pathway [32]. The decrease in the
percentage of VGLUT1-labeled terminals synapsing on spines
could be explained if these terminals made contact with D2-
containing neurons, however, this seems unlikely as recent data
have shown that both types of striatal neurons are similarly
Figure 5. Density of immuno-gold labeled glutamate in asymmetric terminals. (A) In VGLUT1- labeled terminals there was no change in
glutamate density with 6OHDA lesions. In 6OHDA-lesioned rats, STN lesions resulted in a decrease in glutamate particle density in VGLUT1-
immunolabeled terminals (p,0.05), as did STN stimulation (p,0.01). 6OHDA-lesioned rats which underwent STN electrode placement alone did not
show significant changes compared with 6OHDA alone. (B) Glutamate immuno-gold particle density in non-VGLUT1-immunolabeled terminals. There
was no change in glutamate density in 6OHDA-lesioned rats in non-VGLUT1-immunolabeled, thalamostriatal terminals. There was a decrease in
glutamate particle density with STN stimulation (p,0.02) as compared with controls, although only a trend to decrease (p,0.09) compared with
6OHDA-lesioned rats. The decrease with 6OHDA+STN lesions was not significant.
doi:10.1371/journal.pone.0032919.g005
Table 2. Density of immuno-gold-labeled glutamate particles
in post-synaptic spines in which presynaptic terminals were
VGLUT1-labeled or –unlabeled.
Group VGLUT1-labeled Non-VGLUT1-labeled
Control 142.8624.1 149.8612.1
6OHDA 130.1635.2 138.4614.0
6OHDA+STN lesion 103.8656.2 94.6615.3
6OHDA+STN stimulation 77.2628.1 72.9±17.1*
6OHDA+sham stimulation 139.269.8 152.5619.7
Mean 6 standard deviation of number of particles/mm
2.
*significantly different from 6OHDA alone p=0.05.
doi:10.1371/journal.pone.0032919.t002
STN Surgeries and Striatal Glutamate Afferents
PLoS ONE | www.plosone.org 7 March 2012 | Volume 7 | Issue 3 | e32919innervated by both cortical (VGLUT1) and thalamic (VGLUT2)
afferents [14]. In general, a global loss of spines across a large
sample of striatal neurons is reported, rather than a bimodal
distribution [29,30,33–35,57] suggesting a general effect of
dopamine loss upon both striatopallidal and striatonigral neurons.
There is a similar decrease in the numbers of synapses and spines
[27], thus the shift of synapses to shafts with dopamine depletion
cannot be explained by the loss of spines available for synapses.
Following dopamine depletion, we found no differences in the
density of glutamate immuno-gold labeling in either VGLUT1-
labeled or -unlabeled terminals. As presynaptic depletion of
neurotransmitter has been shown to correlate with increased
synaptic release [4,17,58,59], this result contrasts with evidence of
increased striatal extracellular glutamate levels and glutamatergic
activity by us [3,4], and others [13,60–64] and increased
thalamostriatal activity [13,65], at 2–4 weeks following 6OHDA
lesions. Other groups, however, found glutamate levels to be
unchanged [66–68].
Possible explanations for these differences may be the degrees of
dopamine depletion, lesion sites, methodologies and time courses.
However, it is possible that divergence in changes of presynaptic
glutamate labeling and extracellular glutamate levels following
6OHDA lesions indicates that these are controlled by different
mechanisms. Striatal extracellular glutamate levels reflect a
complex balance between neuronal release and non-vesicular
release related to glutamate transporters located upon both
neurons and glia, and the cystine-glutamate antiporter [69,70].
After dopamine depletion changes in glutamatergic neurotrans-
mission within the striatum follow a complex, biphasic pattern
within the first few weeks, possibly stabilizing by 3 months.
Various markers of glutamatergic function have been examined at
different time points, often with contradictory results, including the
cystine-glutamate antiporter [71], and glial transporters [68,72–
75].
Vesicular neuronal glutamate transporters also follow a complex
pattern after 6OHDA lesions. Studies of VGLUT1 found an
increase in levels 3 weeks following dopamine depletion, and a
subsequent decrease, while VGLUT2 levels initially decreased,
then later normalized [76]. In studies of the MPTP-treated
monkey, numbers of VGLUT1 transporters increased, but
VGLUT2 was unchanged [7]. Depending upon their direction
of change, these findings can be interpreted variously as being
primarily responsible for changes in glutamate neurotransmission,
or as compensatory mechanisms.
Striatal vesicular glutamate release is determined by a number
of factors, including the activity of the afferent neurons, and local
modulatory factors such as dopamine [55]. In general, the changes
in presynaptic glutamate labeling found here most closely follow
the changes we found in striatal dopamine levels in parallel
experimental conditions [16], and support a close correlation
between neuronal release of these two neurotransmitters [55,56].
The difference in the current EM results from our previous
report [4] may be due to methodological differences. Although we
demonstrated .90% depletion of SNc TH-immunoreactivity, it is
possible that medial forebrain bundle lesions [4] produced more
complete dopamine depletion. A small percentage difference (from
90% loss of SNc neurons to 95–99% loss) has a large effect upon
striatal metabolism [77,78]. Although we saw comparable
elevations in extracellular glutamate in our two publications
[3,4] the slightly lesser degree of dopamine depletion in the current
study may not have been enough to affect vesicular glutamate
release.
Figure 6. Summary of findings. Compared with control (A), in 6OHDA-lesioned rats, there were relatively more VGLUT-1 labeled terminals making
synapses upon the shafts of dendrites (red circle; B). We hypothesise that this is due to fewer spines being available. There was no change in density
of glutamate labeling. With STN lesions, there was decreased glutamate labeling in VGLUT1-labeled terminals, indicating increased release, indicated
here by increased line thickness (C). With STN stimulation, there was decreased glutamate labeling, suggesting increased release in both types of
terminals, and an increase in the proportion of VGLUT1-labeled terminals upon spines (red circle; D). We did not count spines, but postulate that
there were more spines available for synapses due to plasticity. The relative numbers of VGLUT1-labeled and –unlabeled terminals and their locations
are not accurate.
doi:10.1371/journal.pone.0032919.g006
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6OHDA lesions resulted in a small but significant shift of
VGLUT1-labeled terminals from dendritic spines to shafts. STN
stimulation, but not lesions, returned the locations of these
terminals to the proportions seen in control rats, suggesting that
DBS may achieve its therapeutic effect, at least in part, by
normalization of corticostriatal neurotransmission. This might be
due to stimulation of corticostriatal pathways [51–53], and the
relocation of terminals from shafts to spines, via mechanisms of
synaptic plasticity, and hence increased efficacy of corticostriatal
inputs [15].
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